Back to Search
Start Over
Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review.
- Source :
-
Transfusion & Apheresis Science . Jun2021, Vol. 60 Issue 3, pN.PAG-N.PAG. 1p. - Publication Year :
- 2021
-
Abstract
- We report the case of a patient diagnosed with a clinical relapse of acquired immune-mediated thrombotic thrombocytopenic purpura (TTP) who was successfully treated with low-dose rituximab plus corticosteroids without the use of plasma exchange (PEx), which was unavailable at the time due to the COVID-19 pandemic. Rituximab 100 mg weekly for 4 weeks was administered, combined with 1 mg/kg of prednisone, obtaining a complete hematological response in 6 weeks. This case suggests that PEx may be unnecessary for a subset of patients with relapsed TTP who are clinically stable without significant end-organ damage. A brief literature review regarding TTP patients treated without plasma exchange is also included. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14730502
- Volume :
- 60
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Transfusion & Apheresis Science
- Publication Type :
- Academic Journal
- Accession number :
- 151059015
- Full Text :
- https://doi.org/10.1016/j.transci.2021.103107